NCT00548470

Varenicline Effects In Schizophrenic Smokers

Evaluation of Varenicline's Clinical Efficacy for Continued Smoking Abstinence When Used in the Clinical Treatment of Schizophrenic Patients Hospitalized in an Institution With a Ban on Cigarette Smoking

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: Nathan Kline Institute for Psychiatric Research · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is an open label pre-post study of the effects of clinical treatment with varenicline on 1) decreasing smoking in schizophrenic patients, 2) improving selected cognitive measures in schizophrenic patients, and 3) psychopathology in schizophrenic patients. Patients are assessed on subjective and objective measures of smoking, selected cognitive measures, and special chemical measures, during baseline testing and during 8 weeks of treatment with varenicline (1-2 mg/day).

Conditions

• Schizophrenia
• Tobacco Use Disorder
• Nicotine Dependance

Interventions

Type	Name	Description
DRUG	Varenicline	Varenicline 1-2 mg/day

Timeline

• Start date: 2007-06-01
• Primary completion: 2009-09-01
• Completion: 2010-12-01
• First posted: 2007-10-24
• Last updated: 2018-09-20
• Results posted: 2017-09-05

Locations

1 site across 1 country: United States